keyword
MENU ▼
Read by QxMD icon Read
search

dlqi

keyword
https://www.readbyqxmd.com/read/27911016/positive-impact-of-omalizumab-on-angioedema-and-quality-of-life-in-patients-with-refractory-chronic-idiopathic-spontaneous-urticaria-analyses-according-to-the-presence-or-absence-of-angioedema
#1
M Maurer, H Sofen, B Ortiz, F Kianifard, S Gabriel, J A Bernstein
BACKGROUND: Approximately 50% of patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report hives and angioedema; some experience hives/ angioedema only. OBJECTIVE: Assess omalizumab's effect on angioedema and quality of life (QoL) in subgroups with refractory CIU/CSU: those with and without angioedema. METHODS: Patients received omalizumab (75, 150 or 300 mg) or placebo every 4 weeks for 12/24 weeks. Angioedema and QoL was assessed (Urticaria Patient Daily Diary and Dermatology Quality of Life Index [DLQI])...
December 2, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27906807/quality-of-life-and-sexual-distress-in-women-with-erosive-vulvovaginal-lichen-planus
#2
Harriet Cheng, Amanda Oakley, John V Conaglen, Helen M Conaglen
OBJECTIVES: Erosive vulvovaginal lichen planus (EVLP) is a chronic and painful genital dermatosis. Little is published about its impact on quality of life. This study aimed to evaluate quality of life and sexual function in women with EVLP. MATERIALS AND METHODS: Women with genital dermatoses were surveyed using the Dermatology Life Quality Index (DLQI) and Hospital Depression and Anxiety Scales. A subgroup completed the Female Sexual Distress Scale and Female Sexual Function Index subscales...
November 30, 2016: Journal of Lower Genital Tract Disease
https://www.readbyqxmd.com/read/27897372/azelaic-acid-20%C3%A2-cream-effects-on-quality-of-life-and-disease-severity-in-adult-female-acne-patients
#3
Julius Thomas Kainz, Gabriele Berghammer, Piet Auer-Grumbach, Verena Lackner, Sylvia Perl-Convalexius, Rodica Popa, Barbara Wolfesberger
BACKGROUND: Data on the efficacy of acne treatments and their impact on quality of life (QoL) in adult patients is sketchy. OBJECTIVE: Assessment of the efficacy of azelaic acid 20 % cream (Skinoren(®) ) on acne severity and disease-related QoL. PATIENTS AND METHODS: Noninterventional study in adult female patients with mild to moderate acne. Efficacy variables included DLQI and acne severity on the face, chest, and back using the Investigator's Global Assessment (IGA) scale (grade 1 = nearly clear skin; 2 = mild acne; 3 = moderate acne)...
November 29, 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27874885/patient-reported-outcomes-of-azelaic-acid-foam-15-for-patients-with-papulopustular-rosacea-secondary-efficacy-results-from-a-randomized-controlled-double-blind-phase-3-trial
#4
Stephen Tyring, James A Solomon, Gerald Staedtler, Jason P Lott, Richard Nkulikiyinka, Kaweh Shakery
Patient-reported treatment outcomes are important for evaluating the impact of drug therapies on patient experience. A randomized, double-blind, vehicle-controlled, parallel-group, multicenter, phase 3 study was conducted in 961 participants to assess patient perception of efficacy, utility, and effect on quality of life (QOL) of an azelaic acid (AzA) 15% foam formulation for the treatment of papulopustular rosacea (PPR). Secondary end points included patient-reported global assessment of treatment response, global assessment of tolerability, and opinion on cosmetic acceptability and practicability of product use...
October 2016: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/27862987/einsatz-und-wirksamkeit-von-systemtherapien-bei-erwachsenen-mit-schwerer-neurodermitis-erste-ergebnisse-des-deutschen-neurodermitis-registers-treatgermany
#5
Jochen Schmitt, Susanne Abraham, Freya Trautmann, Victoria Stephan, Regina Fölster-Holst, Bernhard Homey, Thomas Bieber, Natalija Novak, Michael Sticherling, Matthias Augustin, Andreas Kleinheinz, Peter Elsner, Stephan Weidinger, Thomas Werfel
HINTERGRUND: Versorgungsregister dienen der Erfassung des Einsatzes und der Wirksamkeit von Therapien unter realen Versorgungsbedingungen und sind als Basis einer evidenzbasierten Gesundheitsversorgung unverzichtbar. METHODIK: Das deutsche Neurodermitis-Register TREATgermany wurde als weltweit erstes Register für Patienten mit schwerer Neurodermitis 2011 initiiert. Erwachsene mit schwerer Neurodermitis (aktuelle/frühere antientzündliche Systemtherapie und/oder objektiver SCORAD ≥ 40) werden über einen Zeitraum von 24 Monaten prospektiv beobachtet...
November 10, 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27828632/quality-of-life-depression-anxiety-and-loneliness-in-patients-with-bullous-pemphigoid-a-case-control-study
#6
Anargyros Kouris, Eftychia Platsidaki, Christos Christodoulou, Kalliopi Armyra, Panagiota Korkoliakou, Christina Stefanaki, Revekka Tsatovidou, Dimitrios Rigopoulos, George Kontochristopoulos
Background: Bullous pemphigoid (BP) is a chronic, autoimmune blistering skin disease that affects patients' daily life and psychosocial well-being. Objective: The aim of the study was to evaluate the quality of life, anxiety, depression and loneliness in BP patients. Methods: Fifty-seven BP patients and fifty-seven healthy controls were recruited for the study. The quality of life of each patient was assessed using the Dermatology Life Quality Index (DLQI) scale...
September 2016: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/27813140/factors-affecting-patient-presentation-at-a-national-dermatology-referral-clinic-in-kampala-uganda
#7
Eunice S Song, Patrick Musinguzi, Kevin D Dieckhaus
BACKGROUND: This study sought to gain a better understanding of the patient population in Kampala and was further designed to elucidate barriers that may delay individuals from receiving proper dermatologic care. METHODS: The study took place at the dermatovenereology clinic of a tertiary care hospital in Kampala. New adult patients were surveyed in July and August of 2013. The primary dependent variable was time from reported onset of symptoms to presentation to the clinic...
November 4, 2016: International Journal of Dermatology
https://www.readbyqxmd.com/read/27803883/autologous-serum-and-plasma-skin-test-to-predict-2-year-outcome-in-chronic-spontaneous-urticaria
#8
Tadech Boonpiyathad, Atik Sangasapaviliya
BACKGROUND: Autologous serum skin test (ASST) and autologous plasma skin test (APST) are simple methods to diagnose autoimmune chronic urticaria. However, the association data of ASST or APST with disease severity and long-term outcome are still unclear. OBJECTIVE: The results of ASST and APST might be used to predict urticaria symptom severity and long-term outcomes among chronic spontaneous urticaria (CSU) patients. METHODS: We evaluated the prevalence of reactive ASST and APST in 128 CSU patients...
October 2016: Asia Pacific Allergy
https://www.readbyqxmd.com/read/27791446/treatment-patterns-in-moderate-to-severe-plaque-psoriasis-results-from-a-belgian-cross-sectional-study-discover
#9
Julien Lambert, Pierre-Dominique Ghislain, Jo Lambert, Bénédicte Cauwe, Maria Van den Enden
PURPOSE: The present study aimed to evaluate current treatment patterns and achievement of treatment goals in Belgian patients with moderate-to-severe plaque psoriasis. MATERIALS AND METHODS: This cross-sectional observational study (DISCOVER) was conducted in 2011 - 2012 in Belgian dermatology centers. Patient data were collected during a single visit and included information on psoriasis management and severity (PASI and DLQI). Treatment success was defined according to the current European consensus treatment goal algorithm...
November 15, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27785848/characteristics-of-patients-with-plaque-psoriasis-who-have-discordance-between-pasi-and-dlqi-scores
#10
M Amy de la Breteque, A Beauchet, N Quiles-Tsimaratos, E Estève, T Le Guyadec, M Ruer-Mulard, F Maccari, Z Reguiai, C Girard, M Bastien, M Avenel-Audran, C Pauwels, D Bouilly-Auvray, M-L Sigal, E Mahé
Psoriasis has a major physical, psychological and social impact.(1,2) To evaluate physical disease severity, scores are useful. The most frequently used is the psoriasis area and severity index (PASI) which evaluates lesions according to clinical characteristics. It is restricted to plaque psoriasis.(3-5) The most commonly used score to assess the impact on the quality of life (QoL) is the dermatology life quality index (DLQI).(6) It is widely used, translated in many languages, and is considered as a reference to evaluate QoL alteration induced by skin diseases in most of guidelines...
October 27, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27748041/observational-study-on-quality-of-life-safety-and-effectiveness-of-first-line-cetuximab-plus-chemotherapy-in-kras-wild-type-metastatic-colorectal-cancer-patients-the-observer-study
#11
Carmine Pinto, Francesca Di Fabio, Gerardo Rosati, Ivan R Lolli, Enzo M Ruggeri, Libero Ciuffreda, Daris Ferrari, Giovanni Lo Re, Giovanni Rosti, Paolo Tralongo, Raimondo Ferrara, Oscar Alabiso, Silvana Chiara, Giovanni P Ianniello, Antonio Frassoldati, Domenico Bilancia, Giovanna A Campanella, Carlo Signorelli, Patrizia Racca, Elena Benincasa, Maria Elena Stroppolo, Francesco Di Costanzo
Cetuximab improves efficacy when added to chemotherapy for metastatic colorectal cancer (mCRC). Effective management of skin reactions from cetuximab improves quality of life (QoL), and treatment compliance in clinical trials. No data are available from real-world settings. The ObservEr observational, multicenter, prospective study evaluated QoL, the incidence of skin reactions, and management of chemotherapy plus cetuximab in first-line for mCRC. The primary endpoint was QoL measured with the Dermatology Life Quality Index (DLQI) and EORTC QLQ-C30...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27739123/clear-or-almost-clear-skin-improves-the-quality-of-life-in-patients-with-moderate-to-severe-psoriasis-a-systematic-review-and-meta-analysis
#12
Luis Puig, Howard Thom, Patrick Mollon, Haijun Tian, G S Ramakrishna
BACKGROUND: Psoriasis Area and Severity Index (PASI) 75 response is currently considered the gold standard for assessing treatment efficacy in moderate-to-severe psoriatic patients. PASI 90 response denotes better clinical improvement compared to PASI 75. Very few studies have assessed if a greater PASI clinical response is associated with greater improvements in Dermatology Life Quality Index (DLQI). A systematic review and meta-analysis was performed to assess the association between PASI response and DLQI...
October 14, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27737638/severity-and-management-of-psoriasis-within-primary-care
#13
Alan G Wade, Gordon M Crawford, David Young, Joyce Leman, Neil Pumford
BACKGROUND: Scottish Intercollegiate Guidelines Network and National Institute of Health and Care Excellence guidelines stress the importance of assessing patients with psoriasis for psoriatic arthritis, comorbidities associated with severe disease and quality of life (QoL). The purpose of the study was to evaluate the primary care management of psoriasis in relation to disease severity and QoL from a patient's perspective. METHODS: A cross-sectional survey of adults (≥18 years) with psoriasis managed in primary care was conducted in Scotland over 1-year (2012-2013)...
October 14, 2016: BMC Family Practice
https://www.readbyqxmd.com/read/27730628/assessing-the-validity-and-response-distribution-of-the-simplified-psoriasis-index-in-patients-receiving-phototherapy
#14
Nekma Meah, Ali Alsharqi, Richard M Azurdia, Lynne-Catherine Owens, Richard Parslew, Leena Chularojanamontri
BACKGROUND/OBJECTIVES: The simplified psoriasis index (SPI) is a three-part multidimensional tool incorporating disease severity, psychosocial impact and historical course completed by the health-care professional (professional SPI, [proSPI]) or the patient (self-assessment SPI, [saSPI]). We aimed to assess the validity and response distribution of proSPI and saSPI in patients with psoriasis undergoing phototherapy. METHODS: The validity and response distribution of SPI was assessed by recording saSPI and proSPI in patients with psoriasis before and after a course of phototherapy...
October 12, 2016: Australasian Journal of Dermatology
https://www.readbyqxmd.com/read/27716422/a-statistical-analysis-plan-for-the-efficiency-and-safety-of-chinese-herbal-medicine-used-concurrently-with-topical-therapy-for-psoriasis-vulgaris
#15
Liming Lu, Meiling Xuan, Yuhong Yan, Geng Li, Li Zhou, Zehuai Wen, Chuanjian Lu
BACKGROUND: Psoriasis vulgaris (PV) has been causing increasing concern due to its highly prevalent, harmful and therapy-resistant characteristics. The YXBCM01 (Chinese herbal medicine) for PV trial evaluates the effects of YXBCM01 on relapse rate in patients suffering from PV. As an update to the published design and method for the trial, this paper presents the statistical plan for the main publication to avoid the risk of outcome reporting bias, selective reporting, and data-driven results...
October 3, 2016: Trials
https://www.readbyqxmd.com/read/27707593/secukinumab-shows-significant-efficacy-in-palmoplantar-psoriasis-results-from-gesture-a-randomized-controlled-trial
#16
Alice Gottlieb, John Sullivan, Martijn van Doorn, Alexey Kubanov, Ruquan You, Anne Parneix, Sophie Hugot, Marina Milutinovic
BACKGROUND: Plaque psoriasis affecting palms and soles is disabling and often resistant to treatment. OBJECTIVE: Evaluate the efficacy and safety of secukinumab, an anti-interleukin 17A antibody, in subjects with palmoplantar psoriasis. METHODS: In this double-blinded, randomized controlled trial, 205 subjects were randomized 1:1:1 to secukinumab 300 mg, 150 mg, or placebo. The primary endpoint was Palmoplantar Investigator's Global Assessment (ppIGA) 0 (clear) or 1 (almost clear/minimal) response at week 16...
October 1, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27699880/impact-of-uva-on-pruritus-during-uva-b-phototherapy-of-inflammatory-skin-diseases-a-randomized-double-blind-study
#17
Julia-Tatjana Maul, Lorenz Kretschmer, Florian Anzengruber, Andrew Pink, Carla Murer, Lars E French, Günther F L Hofbauer, Alexander A Navarini
BACKGROUND: Narrowband (TL-01) UVB phototherapy (UVB nb) is effective in treating inflammatory skin disease. The addition of UVA is traditionally advocated to reduce pruritus, but lacks evidence for this recommendation. OBJECTIVES: The aim of this study was to assess the effect of UVB nb and UVA phototherapy in combination compared against UVB nb monotherapy on pruritus, disease activity, and quality of life. METHODS: In this double-blind randomised clinical trial 53 patients suffering from inflammatory skin diseases with pronounced itching (Visual Analogue Scale (VAS) for pruritus ≥ 5) were randomised in to two treatment groups...
October 4, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27688440/the-psychosocial-impact-of-acne-vulgaris
#18
Neirita Hazarika, M Archana
BACKGROUND: Acne vulgaris causes erythematous papulopustular lesions in active stage and often leave behind residual scarring and pigmentation. Its onset in adolescence may add to the emotional and psychological challenges experienced during this period. AIMS: To assess the impact of acne on the various psychosocial domains of daily life. MATERIALS AND METHODS: This was a prospective, cross-sectional study done in the dermatology out-patient department of a tertiary care hospital from January to March 2015...
September 2016: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/27680219/a-randomised-half-body-prospective-study-of-low-and-medium-dose-regimens-using-the-308%C3%A2-nm-excimer-laser-in-the-treatment-of-localised-psoriasis
#19
Eleanor Higgins, Nicola Ralph, Sheila Ryan, Nicola Koik, Bahman Honari, Aoife Lally, Paul Collins
This study compared two dose-escalation regimens using the 308 nm excimer laser treating localised plaque psoriasis, to determine the optimal regimen. A randomised, left-right body trial was designed including patients aged >18 years with localised plaque psoriasis (<10% body surface area). The standard/low dose regimen started at 70% of the minimal erythema dose (MED), with 20% dose increments. The medium dose regimen commenced at 200% MED, with 25% increments. Patients were treated until disease clearance or a maximum of 36 treatments...
September 29, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27663079/secukinumab-is-superior-to-ustekinumab-in-clearing-skin-of-subjects-with-moderate-to-severe-plaque-psoriasis-up-to-1%C3%A2-year-results-from-the-clear-study
#20
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot, Ruquan You, Marina Milutinovic, Diamant Thaçi
BACKGROUND: Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis. OBJECTIVE: To compare the efficacy and safety of secukinumab and ustekinumab use over 52 weeks. METHODS: Analysis of 52-week data from CLEAR, a randomized, double-blind, phase 3b study. RESULTS: Among 676 randomized subjects, secukinumab demonstrated superiority to ustekinumab at week 52 in the proportion of subjects with ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) (76% vs 61% [P < ...
September 20, 2016: Journal of the American Academy of Dermatology
keyword
keyword
15510
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"